These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20460482)

  • 1. Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.
    Zhang W; Choi J; Zeng W; Rogers SA; Alyea EP; Rheinwald JG; Canning CM; Brusic V; Sasada T; Reinherz EL; Ritz J; Soiffer RJ; Wu CJ
    Clin Cancer Res; 2010 May; 16(10):2729-39. PubMed ID: 20460482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
    Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
    Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia.
    Yang XF; Wu CJ; McLaughlin S; Chillemi A; Wang KS; Canning C; Alyea EP; Kantoff P; Soiffer RJ; Dranoff G; Ritz J
    Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7492-7. PubMed ID: 11416219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells.
    Wu CJ; Biernacki M; Kutok JL; Rogers S; Chen L; Yang XF; Soiffer RJ; Ritz J
    Clin Cancer Res; 2005 Jun; 11(12):4504-11. PubMed ID: 15958636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.
    Claret EJ; Alyea EP; Orsini E; Pickett CC; Collins H; Wang Y; Neuberg D; Soiffer RJ; Ritz J
    J Clin Invest; 1997 Aug; 100(4):855-66. PubMed ID: 9259585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
    Orsini E; Bellucci R; Alyea EP; Schlossman R; Canning C; McLaughlin S; Ghia P; Anderson KC; Ritz J
    Cancer Res; 2003 May; 63(10):2561-8. PubMed ID: 12750280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
    Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
    Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia.
    Wu CJ; Yang XF; McLaughlin S; Neuberg D; Canning C; Stein B; Alyea EP; Soiffer RJ; Dranoff G; Ritz J
    J Clin Invest; 2000 Sep; 106(5):705-14. PubMed ID: 10974024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells.
    Biernacki MA; Marina O; Zhang W; Liu F; Bruns I; Cai A; Neuberg D; Canning CM; Alyea EP; Soiffer RJ; Brusic V; Ritz J; Wu CJ
    Cancer Res; 2010 Feb; 70(3):906-15. PubMed ID: 20103624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a coordinated allo T cell and auto B cell response against autosomal PTK2B after allogeneic hematopoietic stem cell transplantation.
    Kremer AN; van der Griendt JC; van der Meijden ED; Honders MW; Ayoglu B; Schwenk JM; Nilsson P; Falkenburg JH; Griffioen M
    Haematologica; 2014 Feb; 99(2):365-9. PubMed ID: 24097630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
    Zorn E; Orsini E; Wu CJ; Stein B; Chillemi A; Canning C; Alyea EP; Soiffer RJ; Ritz J
    Transplantation; 2001 Apr; 71(8):1131-7. PubMed ID: 11374415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells.
    von dem Borne PA; van Luxemburg-Heijs SA; Heemskerk MH; Jedema I; Mulder A; Willemze R; Falkenburg JH
    Leukemia; 2006 Jun; 20(6):1040-6. PubMed ID: 16525495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells.
    Kloosterboer FM; van Luxemburg-Heijs SA; van Soest RA; Barbui AM; van Egmond HM; Strijbosch MP; Kester MG; Marijt WA; Goulmy E; Willemze R; Falkenburg JH
    Leukemia; 2004 Apr; 18(4):798-808. PubMed ID: 14973499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of an epitope derived from CML66, a novel tumor-associated antigen expressed broadly in human leukemia, recognized by human leukocyte antigen-A*2402-restricted cytotoxic T lymphocytes.
    Suemori K; Fujiwara H; Ochi T; Azuma T; Yamanouchi J; Narumi H; Yakushijin Y; Hato T; Hasegawa H; Yasukawa M
    Cancer Sci; 2008 Jul; 99(7):1414-9. PubMed ID: 18422754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological effects of donor lymphocyte infusion in patients with chronic myelogenous leukemia relapsing after bone marrow transplantation.
    Castro FA; Palma PV; Morais FR; Voltarelli JC
    Braz J Med Biol Res; 2004 Feb; 37(2):201-6. PubMed ID: 14762574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand.
    Dazzi F; Szydlo RM; Goldman JM
    Exp Hematol; 1999 Oct; 27(10):1477-86. PubMed ID: 10517488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation.
    Smit WM; Rijnbeek M; van Bergen CA; Fibbe WE; Willemze R; Falkenburg JH
    Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10152-7. PubMed ID: 9707616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.
    de Rijke B; van Horssen-Zoetbrood A; Beekman JM; Otterud B; Maas F; Woestenenk R; Kester M; Leppert M; Schattenberg AV; de Witte T; van de Wiel-van Kemenade E; Dolstra H
    J Clin Invest; 2005 Dec; 115(12):3506-16. PubMed ID: 16322791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
    Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
    Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
    Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
    Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.